Logo image of SMMT

SUMMIT THERAPEUTICS INC (SMMT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SMMT - US86627T1088 - Common Stock

17.41 USD
-0.08 (-0.46%)
Last: 12/31/2025, 12:07:10 PM
Fundamental Rating

3

Taking everything into account, SMMT scores 3 out of 10 in our fundamental rating. SMMT was compared to 530 industry peers in the Biotechnology industry. SMMT has a great financial health rating, but its profitability evaluates not so good. SMMT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SMMT had negative earnings in the past year.
In the past year SMMT has reported a negative cash flow from operations.
SMMT had negative earnings in each of the past 5 years.
In the past 5 years SMMT always reported negative operating cash flow.
SMMT Yearly Net Income VS EBIT VS OCF VS FCFSMMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -50.81%, SMMT perfoms like the industry average, outperforming 48.87% of the companies in the same industry.
With a decent Return On Equity value of -56.93%, SMMT is doing good in the industry, outperforming 62.64% of the companies in the same industry.
Industry RankSector Rank
ROA -50.81%
ROE -56.93%
ROIC N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
SMMT Yearly ROA, ROE, ROICSMMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SMMT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMMT Yearly Profit, Operating, Gross MarginsSMMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

SMMT has more shares outstanding than it did 1 year ago.
SMMT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SMMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SMMT Yearly Shares OutstandingSMMT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SMMT Yearly Total Debt VS Total AssetsSMMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

SMMT has an Altman-Z score of 162.43. This indicates that SMMT is financially healthy and has little risk of bankruptcy at the moment.
SMMT has a better Altman-Z score (162.43) than 99.43% of its industry peers.
SMMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 162.43
ROIC/WACCN/A
WACCN/A
SMMT Yearly LT Debt VS Equity VS FCFSMMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 10.15 indicates that SMMT has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.15, SMMT belongs to the best of the industry, outperforming 81.51% of the companies in the same industry.
A Quick Ratio of 10.15 indicates that SMMT has no problem at all paying its short term obligations.
The Quick ratio of SMMT (10.15) is better than 81.51% of its industry peers.
Industry RankSector Rank
Current Ratio 10.15
Quick Ratio 10.15
SMMT Yearly Current Assets VS Current LiabilitesSMMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

SMMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -122.22%.
EPS 1Y (TTM)-122.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-287.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SMMT will show a very strong growth in Earnings Per Share. The EPS will grow by 47.12% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-297.74%
EPS Next 2Y-76.71%
EPS Next 3Y-41.19%
EPS Next 5Y47.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SMMT Yearly Revenue VS EstimatesSMMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B 8B
SMMT Yearly EPS VS EstimatesSMMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SMMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SMMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMMT Price Earnings VS Forward Price EarningsSMMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SMMT Per share dataSMMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as SMMT's earnings are expected to decrease with -41.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-76.71%
EPS Next 3Y-41.19%

More info and screens

0

5. Dividend

5.1 Amount

SMMT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SUMMIT THERAPEUTICS INC

NASDAQ:SMMT (12/31/2025, 12:07:10 PM)

17.41

-0.08 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-20 2025-10-20/bmo
Earnings (Next)02-23 2026-02-23/bmo
Inst Owners14.44%
Inst Owner Change6.47%
Ins Owners86.05%
Ins Owner Change2.45%
Market Cap12.96B
Revenue(TTM)N/A
Net Income(TTM)-221.31M
Analysts78.26
Price Target33.08 (90.01%)
Short Float %34.44%
Short Ratio12.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.94%
Min EPS beat(2)-17.64%
Max EPS beat(2)3.77%
EPS beat(4)2
Avg EPS beat(4)-13.56%
Min EPS beat(4)-42.31%
Max EPS beat(4)3.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.44%
PT rev (3m)-5.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)6.13%
EPS NY rev (3m)-15.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 33.34
P/tB 33.5
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.81%
ROE -56.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.89%
ROA(5y)-99.04%
ROE(3y)-303.53%
ROE(5y)-216.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 156.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.15
Quick Ratio 10.15
Altman-Z 162.43
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)90.01%
Cap/Depr(5y)64.02%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-122.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-287.5%
EPS Next Y-297.74%
EPS Next 2Y-76.71%
EPS Next 3Y-41.19%
EPS Next 5Y47.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-137.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-123.2%
EBIT Next 3Y-53.6%
EBIT Next 5YN/A
FCF growth 1Y-85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.13%
OCF growth 3YN/A
OCF growth 5YN/A

SUMMIT THERAPEUTICS INC / SMMT FAQ

Can you provide the ChartMill fundamental rating for SUMMIT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SMMT.


What is the valuation status of SUMMIT THERAPEUTICS INC (SMMT) stock?

ChartMill assigns a valuation rating of 0 / 10 to SUMMIT THERAPEUTICS INC (SMMT). This can be considered as Overvalued.


What is the profitability of SMMT stock?

SUMMIT THERAPEUTICS INC (SMMT) has a profitability rating of 1 / 10.


How financially healthy is SUMMIT THERAPEUTICS INC?

The financial health rating of SUMMIT THERAPEUTICS INC (SMMT) is 8 / 10.